Institutional investors hold a majority ownership of CASC through the 59.54% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2016, these large investors purchased a net $22.5 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
APO ASSET MANAGEMENT GMBH Bought 309.4 Thousand shares of Cascadian Therapeutics In...